IMI Antimicrobial resistance accelerator programme

IMI (Innovative Medicines Initiative) recently published topics under consideration for  inclusion in future IMI Calls for proposals.

One of the programme focus and Antimicrobial resistance with 3 pillars:

Pillar A: Capability building network (CBN)
Pillar B: Tuberculosis drug development network (TBDDN)
Pillar C: Company-specific portfolio building networks (PBNs)


More informations and drafts topic texts are available on IMI Future Topics page.


The NAREB project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 604237.